Truist Sees Upside in BridgeBio Pharma's (BBIO) ATTR-CM Strategy

BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 21, Truist Securities initiated coverage of BBIO with a Buy rating and a $66 price target, spotlighting the promising launch of Attruby for treating ATTR-CM.

Citing its growing use as a first-line therapy due to ease of access and better stabilizer data, Truist sees strong traction among tafamidis-progressing patients.

With the ATTR-CM market expected to reach $20 billion, Truist views significant upside for Attruby despite ongoing patent litigation from Pfizer. The firm remains optimistic about BridgeBio’s IP position and also highlighted near-term growth catalysts from its late-stage pipeline, particularly starting in the second half of 2025.

BridgeBio Pharma Inc. (NASDAQ:BBIO) is a biopharmaceutical company that develops and delivers transformative medicines for genetic diseases and cancers with clear genetic drivers. It boasts a pipeline of candidate drugs, some in early-stage research and others in advanced clinical trials.

While we acknowledge the potential of BBIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Airline Stocks to Buy According to Hedge Funds and Goldman Sachs REIT Stocks: Top 12 Stock Picks.

Disclosure: None. This article is originally published at Insider Monkey.